

National Oesophago-Gastric Cancer Audit

Aneurin Bevan University Health Board

South Wales, Welsh Region

Management of High Grade Dysplasia patients

Time period: 2018-22

| | Welsh Region | National |
|---|--------------|----------|
| Number of High Grade Dysplasia patients in audit | N/A | 1120 |
| | Welsh Region | National |
| Method of Diagnosis | | |
| – First diagnosis confirmed by second pathologist | N/A | 90.0% |
| Treatment planning | | |
| – HGD plan discussed at MDT | N/A | 93.0% |
| – Treatment plan for active treatment | N/A | 82.0% |
| First treatment | | |
| – Endoscopic therapy (such as endoscopic resection) | N/A | 78.0% |
| – Surveillance | N/A | 11.0% |

NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.

Management of oesophago-gastric cancer patients

Time period: 2020-2022

| | Organisation | | National |
|---|--------------|-------|----------|
| Number of oesophago-gastric (OG) cancer patients in audit | 225 | | 19,865 |
| Case ascertainment for OG cancer (%) | 85-100% | | |
| Method of Diagnosis | | | |
| – Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations | 29 | 14.1% | 13.1% |
| – Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
| Pre-treatment staging of cancer | | | |
| – Patients having staging CT scan recorded | 218 | 96.9% | 94.0% |
| Treatment planning | | | |
| – Patients having a plan for curative treatment | 73 | 32.4% | 37.2% |
| – Patients having a plan for non-curative treatment | 152 | 67.6% | 62.8% |
| – Patients with non-curative plans having chemotherapy or radiotherapy | 65 | 42.8% | 34.7% |